摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3aS,4Z,6aR)-5-{hexahydro-1,3-dibenzyl-2-oxo-4H-thieno[3,4-d]imidazol-4-ylidene}pentanoic acid | 452100-87-7

中文名称
——
中文别名
——
英文名称
(3aS,4Z,6aR)-5-{hexahydro-1,3-dibenzyl-2-oxo-4H-thieno[3,4-d]imidazol-4-ylidene}pentanoic acid
英文别名
(5Z)-5-[(3aS,6aR)-1,3-dibenzyl-2-oxo-6,6a-dihydro-3aH-thieno[3,4-d]imidazol-4-ylidene]pentanoic acid
(3aS,4Z,6aR)-5-{hexahydro-1,3-dibenzyl-2-oxo-4H-thieno[3,4-d]imidazol-4-ylidene}pentanoic acid化学式
CAS
452100-87-7
化学式
C24H26N2O3S
mdl
——
分子量
422.548
InChiKey
GQKNDJQLKMPRRK-GHWJVACZSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    84-85 °C
  • 沸点:
    676.8±55.0 °C(Predicted)
  • 密度:
    1.324±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    30
  • 可旋转键数:
    8
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    86.2
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Intermediate for biotin and process for producing the same
    申请人:Seki Masahiko
    公开号:US20050038260A1
    公开(公告)日:2005-02-17
    The present invention is to provide a process for preparing a synthetic intermediate of biotin which is industrially advantageous, and discloses a process for preparing a compound represented by the formula (I): wherein R 1 and R 2 may be the same or different from each other, and each represents hydrogen atom, a benzyl group which may have a substituent(s) on the benzene ring, a benzhydryl group which may have a substituent(s) on the benzen ring, or a trityl group which may have a substituent(s) on the benzene ring, R 3 represents cyano group, carboxyl group, an alkoxycarbonyl group, an alkylthiocarbonyl group, or a carbamoyl group which may have a substituent, or a salt thereof which comprises subjecting a compound represented by the formula (II-a): wherein the symbols have the same meanings as defined above, or a salt thereof to ring transformation.
    本发明提供了一种制备生物素合成中间体的工业优势过程,并披露了一种制备由式(I)表示的化合物的过程:其中R1和R2可以相同也可以不同,分别代表氢原子、苯甲基,苯环上可能带有取代基的苯甲基,苯环上可能带有取代基的苯基甲基,或苯环上可能带有取代基的三苯甲基;R3代表氰基、羧基、烷氧基羰基、烷基硫酰基、或可能带有取代基的氨基甲酰基,或其盐;该过程包括将式(II-a)表示的化合物:其中符号具有上述定义的相同含义,或其盐进行环转化。
  • Biotin intermediate and process for preparing the same
    申请人:Seki Masahiko
    公开号:US20080119655A1
    公开(公告)日:2008-05-22
    The present invention is to provide a process for preparing a synthetic intermediate of biotin which is industrially advantageous, and discloses a process for preparing a compound represented by the formula (I): 1 wherein R 1 and R 2 may be the same or different from each other, and each represents hydrogen atom, a benzyl group which may have a substituent(s) on the benzene ring, a benzhydryl group which may have a substituent(s) on the benzen ring, or a trityl group which may have a substituent(s) on the benzene ring, R 3 represents cyano group, carboxyl group, an alkoxycarbonyl group, an alkylthiocarbonyl group, or a carbamoyl group which may have a substituent, or a salt thereof which comprises subjecting a compound represented by the formula (II-a): 2 wherein the symbols have the same meanings as defined above, or a salt thereof to ring transformation.
    本发明提供了一种制备生物素合成中间体的工业优势过程,并揭示了一种制备由式(I)表示的化合物的过程:其中R1和R2可以相同也可以不同,分别表示氢原子,苯基(苯环上可能有取代基),苯基甲基(苯环上可能有取代基),或三苯甲基(苯环上可能有取代基);R3表示氰基,羧基,烷氧基羰基,烷基硫氧基羰基或氨基甲酰基(可能带有取代基),或其盐,该过程包括将式(II-a)表示的化合物:其中符号具有上述定义的相同含义,或其盐进行环转化。
  • Verfahren zur Herstellung von D-(+)-Biotin
    申请人:MERCK PATENT GmbH
    公开号:EP0242686A2
    公开(公告)日:1987-10-28
    D-(+)-Biotin kann aus optisch aktiven Hydantoinen der Formel I, worin R1, R2, R3, X und Y die in Patentanspruch 1 angegebene Bedeutung besitzen, auf einfache und stereospezifische Weise hergestellt werden. Dabei stellt das bicyclische Nitril der Formel XI, worin R1, R2, R3, X und Y die angegebene Bedeutung besitzen, ein wertvolles Zwischen- und Ausgangsprodukt einer Vielzahl von Synthesemöglichkeiten für optisch aktives D-(+)-Biotin dar.
    D-(+)- 生物素可由式 I 的光学活性海因制备、 其中 R1、R2、R3、X 和 Y 具有权利要求 1 所述的含义。 式 XI.的双环腈、 其中 R1、R2、R3、X 和 Y 的含义如权利要求 1 所述。 是合成光学活性 D-(+)-生物素的重要中间体和起始产物。
  • INTERMEDIATE FOR BIOTIN AND PROCESS FOR PRODUCING THE SAME
    申请人:Mitsubishi Tanabe Pharma Corporation
    公开号:EP1462444B1
    公开(公告)日:2009-09-16
  • OXASI, TEHRUDZI;IKEHDA, TAKAXARU;SIMADZI, TAKADZO;TAKAXASI, TAKEHO;ISIKUR+
    作者:OXASI, TEHRUDZI、IKEHDA, TAKAXARU、SIMADZI, TAKADZO、TAKAXASI, TAKEHO、ISIKUR+
    DOI:——
    日期:——
查看更多

同类化合物

生物素-C5-叠氮 樟磺咪芬 四氢-4-(5-羟戊基)-(3AS,4S,6AR)-1H-噻吩并[3,4-D]咪唑-2(3H)-酮 咪噻吩 利地霉素 5-硫杂-1,2A-二氮杂环戊并[Cd]并环戊二烯 1,3-二苄基-2-氧代十氢噻吩并[1',2':1,2]噻吩并[3,4-d]咪唑-5-鎓溴化物 (3AS,4S,6AR)-1,3-二苄基-2-氧代六氢-1H-噻吩并[3,4-d]咪唑-4-甲醛 (3aS,4S,6aR)-4-(5-(1-(2-hydroxybenzyl)-1H-1,2,3-triazol-4-yl)pentyl)tetrahydro-1H-thieno[3,4-d]imidazol-2(3H)-one (3aS,4S,6aR)-4-(5-(1-(3-methoxybenzyl)-1H-1,2,3-triazol-4-yl)pentyl)tetrahydro-1H-thieno[3,4-d]imidazol-2(3H)-one methyl (4E,Z)-6-({5-[(3aS,4S,6aR)-1,3-bis(4-methoxybenzyl)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentyl}oxy)hex-4-enoate 1H-thieno<3,4-d>imidazol-2(3H)-one, tetrahydro-4-(5-chloropentyl)-, <3aS-(3aα,4β,6aα)>- (3aS,4Z,6aR)-5-{hexahydro-2-oxo-4H-thieno[3,4-d]imidazol-4-ylidene}pentanoic acid methyl ester (3aS,6aR)-1,3-dibenzyl-tetrahydro-1H-thieno[3,4-d]-imidazole-2(3H)-one-4-yl-pentanoic acid (3aS,4S,6aR)-4-(5-(1-(4-iodobenzyl)-1H-1,2,3-triazol-4-yl)pentyl)tetrahydro-1H-thieno[3,4-d]imidazol-2(3H)-one 1-amino-17-N-(biotinylamido)-3,6,9,12,15-pentaoxaheptadecane (3aS,4S,6aR)-4-(4-isocyanatobutyl)tetrahydro-1H-thieno[3,4-d]imidazol-2(3H)-one 2-[1-Hydroxy-5-((3aR,6S,6aS)-2-oxo-hexahydro-thieno[3,4-d]imidazol-6-yl)-pentylidene]-5,5-dimethyl-cyclohexane-1,3-dione (3aS,4S,6aR)-4-(4-aminobut-1-yl)hexahydro-1H-thieno[3,4-d]imidazolidin-2-one hydrochloride Methyl-bisnorbiotinyl-keton 3,4-(1',3'-Dibenzyl-2'-oxoimidazolido)-2-hydroxy-thiophen 5-[({4-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]butyl}carbamoyl)amino]pentanoic acid tert-butyl 5-[({4-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]butyl}carbamoyl)amino]pentanoate 1-{5-[(2,5-dioxopyrrolidin-1-yl)oxy]-5-oxopentyl}-3-{4-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]butyl}urea Trimetaphan camsylate (3aS,4S,6aR)-4-hexyl-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-2-one 1-Benzyl-1,3a,4,6,7,8,8a,8b-octahydrothieno[1',2':1,2]thieno[3,4-d]imidazol-5-ium-2-olate--hydrogen chloride (1/1) (3aα,6aα)-1H-thieno<3,4-d>imidazol-2(3H)-one 5,5-dioxide (3aα,6aα)-1,3-dibenzylhexahydro-1H-thieno<3,4-d>imidazole (3aα,6aβ)-1,3-dibenzylhexahydro-1H-thieno<3,4-d>imidazol-2(3H)-one 5,5-dioxide (3aα,6aα)-1,3-dibenzylhexahydro-1H-thieno<3,4-d>imidazol-2(3H)-one 5,5-dioxide (E)-5-(2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl)pent-2-enoic acid (3aS,4Z,6aR)-1,3-dibenzyl-4-(3-methoxypropylidene)-6,6a-dihydro-3aH-thieno[3,4-d]imidazol-2-one (3aS,6aR)-1-Isopropyl-5,5-dioxo-hexahydro-5λ6-thieno[3,4-d]imidazol-2-one (3AS-cis)-1,3-dibenzyltetrahydro-4-(3-methoxypropylidene)-1H-thieno(3,4-d)imidazol-2(3H)-one (3ar,6ac)-tetrahydro-thieno[3,4-d]imidazol-2-one 2-oxo-(3ar,3bξ,8ac)-decahydro-thieno[1',2':1,2]thieno[3,4-b]imidazolium; bromide biotin hydrazide (3aS,4S,6aR)-1,3-bis[(3-bromophenyl)methyl]-4-(5-hydroxypentyl)-3a,4,6,6a-tetrahydrothieno[3,4-d]imidazol-2-one 4-Pentyl-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-2-one (3aS,4S,6aR)-3-benzyl-4-pentyl-3a,4,6,6a-tetrahydro-1H-thieno[3,4-d]imidazol-2-one (3aS,4S,6aR)-4-hept-6-ynyl-2-oxo-tetrahydro-thieno[3,4-d]imidazole-1,3-dicarboxylic acid di-tert-butyl ester (3aS,4S,6aR)-4-(6-hydroxyhexyl)-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-2-one (3aS,4S,6aR)-4-oct-7-ynyl-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-2-one 6-(methyl{5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentyl}amino)hexanoic acid 5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentyl dimethyl phosphite Methyl-tetranorbiotinyl-keton (2aR,7aS,7bS)-Hexahydro-2H-1-thia-3,4a-diazacyclopent[cd]inden-4(3H)-one 8-(2-Oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)octanoic acid 2'-thiobiotinol